Get In Touch
Work Inquiries

Three cannabis chemotypes differentiated at genome level, not only related with THC and CBD production

PBG BioPharma has launched a series of studies under their Health Canada approved cannabis research license, proposing that a new classification system be established for cannabis based on genome-wide variation and supplemented by data on secondary metabolites and morphological characteristics.

Leveraging as much genetic variation as possible using whole-genome sequencing, research scientists at PBG BioPharma have identified structural SNPs as genomic fingerprints that can be used to differentiate three cannabis chemotypes- CBD dominant, intermediate, and THC dominant chemotypes. Results have shown that the genetic differences between modern cannabis strains were at a whole-genome level and not limited to THC or CBD production. These fingerprint markers can facilitate our proprietary technology platform, GenBioChem® Triple Fingerprinting Technology™, which ensures quality, authenticity and purity throughout our entire production cycle from lab to shelf. Related work has been submitted to peer-reviewed journals and under final rounds of review.

Read more about cannabis botanical vs. vernacular naming conventions and classifications prepared by our PBG BioPharma scientists:


The freshest cannabis content, right to your inbox.

Sign up to receive the latest developments in cannabis science every week.

We don’t spam! Read our privacy policy for more info.

Author avatar
Dr. Dan Jin
Dr. Dan Jin is the resident Cannabis Research Scientist at PBG BioPharma. She has over 10 publications to her name in the field of cannabis research. She is a passionate force in researching novel uses of cannabis and educating the public about the potential of this incredible plant.

Post a comment

Your email address will not be published. Required fields are marked *

We use cookies to give you the best experience.